Prof. Allan Bradley
Co-founder
Allan is a genome engineering pioneer, coupling science wisdom of extensive publication and institute leaderships with the founder wisdom of 2 unicorns and 1 IPO. To ExEd, he brings his invaluable advice both on the science as well as strategy front.
Bio
Allan is a world-renowned researcher and entrepreneur. He completed his PhD studies in genetics at the University of Cambridge in 1984. Working with Liz Robertson in the laboratory of Martin Evans, who shared the Nobel Prize for Physiology or Medicine in 2007, they showed that embryonic stem cells could be used to stably modify mouse genes. In 1987 Professor Bradley moved to Baylor College of Medicine, Houston, Texas, where his laboratory developed novel methods to engineer the genomes of mice. He was appointed Investigator with the Howard Hughes Medical Institute in 1993 and full Professor in 1994. In 2000, Dr Bradley returned to the UK as Director of the Wellcome Trust Sanger Institute where he was responsible for transitioning its high-throughput genome-sequencing infrastructure into an academic genome center with a focus on primary research.
Professor Bradley is the author of almost 300 scientific articles and book chapters and has been a Fellow of the Royal Society since July 2002. He has been active in commercializing technology from his laboratory by founding several companies including a publicly traded genomics company, Lexicon Genetics Inc, and two antibody platform companies Petmedix Ltd an Kymab Ltd which was recently acquired by Sanofi.
Allan is a genome engineering pioneer, coupling science wisdom of extensive publication and institute leaderships with the founder wisdom of 2 unicorns and 1 IPO. To ExEd, he brings his invaluable advice both on the science as well as strategy front.
Bio
Allan is a world-renowned researcher and entrepreneur. He completed his PhD studies in genetics at the University of Cambridge in 1984. Working with Liz Robertson in the laboratory of Martin Evans, who shared the Nobel Prize for Physiology or Medicine in 2007, they showed that embryonic stem cells could be used to stably modify mouse genes. In 1987 Professor Bradley moved to Baylor College of Medicine, Houston, Texas, where his laboratory developed novel methods to engineer the genomes of mice. He was appointed Investigator with the Howard Hughes Medical Institute in 1993 and full Professor in 1994. In 2000, Dr Bradley returned to the UK as Director of the Wellcome Trust Sanger Institute where he was responsible for transitioning its high-throughput genome-sequencing infrastructure into an academic genome center with a focus on primary research.
Professor Bradley is the author of almost 300 scientific articles and book chapters and has been a Fellow of the Royal Society since July 2002. He has been active in commercializing technology from his laboratory by founding several companies including a publicly traded genomics company, Lexicon Genetics Inc, and two antibody platform companies Petmedix Ltd an Kymab Ltd which was recently acquired by Sanofi.
Allan is a genome engineering pioneer, coupling science wisdom of extensive publication and institute leaderships with the founder wisdom of 2 unicorns and 1 IPO. To ExEd, he brings his invaluable advice both on the science as well as strategy front.
Bio
Allan is a world-renowned researcher and entrepreneur. He completed his PhD studies in genetics at the University of Cambridge in 1984. Working with Liz Robertson in the laboratory of Martin Evans, who shared the Nobel Prize for Physiology or Medicine in 2007, they showed that embryonic stem cells could be used to stably modify mouse genes. In 1987 Professor Bradley moved to Baylor College of Medicine, Houston, Texas, where his laboratory developed novel methods to engineer the genomes of mice. He was appointed Investigator with the Howard Hughes Medical Institute in 1993 and full Professor in 1994. In 2000, Dr Bradley returned to the UK as Director of the Wellcome Trust Sanger Institute where he was responsible for transitioning its high-throughput genome-sequencing infrastructure into an academic genome center with a focus on primary research.
Professor Bradley is the author of almost 300 scientific articles and book chapters and has been a Fellow of the Royal Society since July 2002. He has been active in commercializing technology from his laboratory by founding several companies including a publicly traded genomics company, Lexicon Genetics Inc, and two antibody platform companies Petmedix Ltd an Kymab Ltd which was recently acquired by Sanofi.
→